- Home
- BTAI
BTAI
BioXcel Therapeutics Inc.
as 04-23-2025 4:00pm EST
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | N/A | IPO Year: | 2018 |
| Target Price: | $42.60 | AVG Volume (30 days): | 122.1K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.29 - $48.72 | Next Earning Date: | 05-08-2025 |
| Revenue: | $2,266,000 | Revenue Growth: | 64.20% |
| Revenue Growth (this year): | 41% | Revenue Growth (next year): | 197.21% |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
a month ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
Zacks
a month ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
GlobeNewswire
a month ago
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Insider Monkey
a month ago
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week
GlobeNewswire
2 months ago
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Zacks
2 months ago
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
Compare BTAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.